Fig. 3

Pre-elevated IOP treatment with ONL1204 protects RGCs and prevents axon degeneration in microbead-induced model of glaucoma. WT C57BL/6J mice received an intravitreal injection of ONL1204 (2 μg/1 μl injection) or vehicle only, immediately followed by an anterior chamber injection of microbeads or saline (day 0). a IOP measurements were taken by rebound tonometry every 3–4 days. Data is presented as mean IOP ± SD, N = 8 mice per group. IOP was significantly elevated on days 3–21 in microbead-injected WT mice treated with ONL1204 or vehicle when compared to saline-injected WT controls treated with ONL1204 or vehicle (****P < 0.0001). b Representative confocal images of retinal flatmounts isolated at 28 days post-microbead or saline injection and stained with an anti-Brn3a antibody (red, an RGC-specific marker) and a DAPI nuclear stain (blue) (scale bar, 50 μm). c Quantification of Brn3a-positive RGCs represented as the mean RGC density/mm² retina ± SD. N = 8 per group, ***P < 0.001, ****P < 0.0001. d Representative photomicrographs of PPD-stained optic nerve cross-sections at 28 days post-microbead or saline injections (scale bar, 20 μm). e Quantification of healthy axons represented as the mean axon density (10⁴)/mm² ON ± SD. N = 8 per group, ***P < 0.001, ****P < 0.0001